TEL-AVIV,
Israel and RALEIGH, N.C., Oct 3 (GLOBE NEWSWIRE) -- RedHill Biopharma
Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”),
a specialty biopharmaceutical company primarily focused on late clinical-stage
development and commercialization of proprietary, orally-administered, small molecule
drugs for gastrointestinal and inflammatory diseases and cancer, today
announced that the Company has accelerated the timelines for the ongoing first
Phase III study with RHB-104 for Crohn’s disease (MAP US) by curtailing the
number of subjects planned to be enrolled in the study from 410 to
approximately 325 subjects.
Given
that 322 subjects have been enrolled in the MAP US Phase III study to date, the
Company expects to complete enrollment by November 2017 and to announce
top-line results in mid-2018. RedHill remains blinded to the ongoing data from
the study. The protocol amendment implementing the curtailment strategy has
been filed with the FDA and healthcare regulators in other relevant countries.
Source : RedHill Biopharma Ltd.
No comments:
Post a Comment